At the time of writing, Zimmer Biomet Holdings Inc [ZBH] stock is trading at $127.36, up 1.22%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ZBH shares have gain 2.41% over the last week, with a monthly amount drifted -0.19%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 22, February 2024, Zimmer Biomet Receives FDA Clearance for ROSA® Shoulder System – the World’s First Robotic Assistant for Shoulder Replacement Surgery. In a post published today on Yahoo Finance, The ROSA® Shoulder System Becomes the First-to-Market Robotic Surgical Assistant for Shoulder Arthroplasty and the Fourth ROSA Robotics Application in Five Years.
From an analyst’s perspective:
Zimmer Biomet Holdings Inc [NYSE: ZBH] stock has seen the most recent analyst activity on January 04, 2024, when Evercore ISI downgraded its rating to a In-line and also revised its price target to $125 from $135. Previously, ROTH MKM started tracking the stock with Neutral rating on October 20, 2023, and set its price target to $120. On August 28, 2023, upgrade upgraded it’s rating to Buy but maintained its price target of $139 on the stock. BofA Securities upgraded its rating to a Neutral. Evercore ISI upgraded its rating to a Outperform and raised its price target to $148 on April 11, 2023. Jefferies upgraded its rating to Hold for this stock on March 31, 2023, and upped its price target to $130. In a note dated March 29, 2023, UBS initiated an Sell rating and provided a target price of $112 on this stock.
For the past year, the stock price of Zimmer Biomet Holdings Inc fluctuated between $102.00 and $149.25. Currently, Wall Street analysts expect the stock to reach $142.2 within the next 12 months. Zimmer Biomet Holdings Inc [NYSE: ZBH] shares were valued at $127.36 at the most recent close of the market. An investor can expect a potential return of 11.65% based on the average ZBH price forecast.
Analyzing the ZBH fundamentals
According to Zimmer Biomet Holdings Inc [NYSE:ZBH], the company’s sales were 7.39B for trailing twelve months, which represents an 6.30% jump. Gross Profit Margin for this corporation currently stands at 0.72% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.14%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.08 and Total Capital is 0.07. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 126.35 points at the first support level, and at 125.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 128.25, and for the 2nd resistance point, it is at 129.15.
Zimmer Biomet Holdings Inc [ZBH] reported earnings per share of $2.2 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $2.15/share, meaning a difference of $0.05 and a surprise factor of 2.30%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $1.65 per share as compared to estimates of $1.6 per share, a difference of $0.05 representing a surprise of 3.10%.
Ratios To Look Out For
It is important to note that Zimmer Biomet Holdings Inc [NYSE:ZBH] has a current ratio of 1.61. In addition, the Quick Ratio stands at 0.78 and the Cash Ratio stands at 0.15. Considering the valuation of this stock, the price to sales ratio is 3.53, the price to book ratio is 2.10 and price to earnings (TTM) ratio is 26.06.
Transactions by insiders
Recent insider trading involved Phipps Chad F, Sr. VP/Gen Counsel/Secretary, that happened on Feb 22 ’24 when 26156.0 shares were sold. Director, Jafry Syed A. completed a deal on Nov 09 ’23 to buy 2135.0 shares. Meanwhile, Director Kolli Sreelakshmi bought 1000.0 shares on Aug 30 ’23.
